VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q57325705  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010844.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q57325705‏
024 ‎‡a  0000-0002-9486-1885‏ ‎‡2  orcid‏
024 ‎‡a  0000-0003-1007-2393‏ ‎‡2  orcid‏
024 ‎‡a  7403982206‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q57325705‏
100 0 ‎‡a  Jonathan C Levy‏ ‎‡9  it‏ ‎‡9  es‏ ‎‡9  ast‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Jonathan Cummings Levy‏ ‎‡c  researcher ORCID: 0000-0002-9486-1885‏ ‎‡9  en‏
400 0 ‎‡a  Jonathan C Levy‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population‏
670 ‎‡a  Author's A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q‏
670 ‎‡a  Author's A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk‏
670 ‎‡a  Author's A method for assessing quality of control from glucose profiles.‏
670 ‎‡a  Author's Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes‏
670 ‎‡a  Author's An association analysis of the HLA gene region in latent autoimmune diabetes in adults.‏
670 ‎‡a  Author's An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.‏
670 ‎‡a  Author's Analysis of the contribution to type 2 diabetes susceptibility of sequence variation in the gene encoding stearoyl-CoA desaturase, a key regulator of lipid and carbohydrate metabolism‏
670 ‎‡a  Author's Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes‏
670 ‎‡a  Author's Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes‏
670 ‎‡a  Author's Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility‏
670 ‎‡a  Author's Association Studies of Insulin Receptor Substrate 1 Gene‏
670 ‎‡a  Author's Association Studies of Insulin Receptor Substrate 1 Gene (IRS1) Variants in Type 2 Diabetes Samples Enriched for Family History and Early Age of Onset‏
670 ‎‡a  Author's Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.‏
670 ‎‡a  Author's Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance.‏
670 ‎‡a  Author's Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial.‏
670 ‎‡a  Author's Determinants of within-subject variation of fasting serum leptin concentrations in healthy subjects.‏
670 ‎‡a  Author's Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido‏
670 ‎‡a  Author's Erectile dysfunction in diabetes mellitus.‏
670 ‎‡a  Author's Erratum: Sequence data and association statistics from 12,940 type 2 diabetes cases and controls‏
670 ‎‡a  Author's Ethnic differences in sexual dysfunction among diabetic and nondiabetic males: the Oxford Sexual Dysfunction Study‏
670 ‎‡a  Author's Evidence for linkage of stature to chromosome 3p26 in a large U.K. Family data set ascertained for type 2 diabetes‏
670 ‎‡a  Author's Evidence From a Large U.K. Family Collection That Genes Influencing Age of Onset of Type 2 Diabetes Map to Chromosome 12p and to the MODY3/NIDDM2 Locus on 12q24‏
670 ‎‡a  Author's Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes-related traits in UK samples.‏
670 ‎‡a  Author's GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes‏
670 ‎‡a  Author's GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77‏
670 ‎‡a  Author's Glucokinase deficiency results in a beta-cell disorder characterised by normal fasting plasma proinsulin concentrations.‏
670 ‎‡a  Author's Glucose tolerance in rural diabetic Thais, first-degree relatives and non-diabetic controls.‏
670 ‎‡a  Author's Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes‏
670 ‎‡a  Author's Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.‏
670 ‎‡a  Author's Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.‏
670 ‎‡a  Author's Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.‏
670 ‎‡a  Author's Impending type 2 diabetes.‏
670 ‎‡a  Author's Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease‏
670 ‎‡a  Author's Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).‏
670 ‎‡a  Author's Interaction between specific fatty acids, GLP-1 and insulin secretion in humans‏
670 ‎‡a  Author's Islet amyloid polypeptide gene promoter polymorphisms are not associated with Type 2 diabetes or with the severity of islet amyloidosis‏
670 ‎‡a  Author's Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2‏
670 ‎‡a  Author's Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes‏
670 ‎‡a  Author's Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes.‏
670 ‎‡a  Author's Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility‏
670 ‎‡a  Author's Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1‏
670 ‎‡a  Author's Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.‏
670 ‎‡a  Author's No Evidence for Linkage at Candidate Type 2 Diabetes Susceptibility Loci on Chromosomes 12 and 20 in United Kingdom Caucasians‏
670 ‎‡a  Author's Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups‏
670 ‎‡a  Author's Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome‏
670 ‎‡a  Author's Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.‏
670 ‎‡a  Author's PTEN mutations as a cause of constitutive insulin sensitivity and obesity.‏
670 ‎‡a  Author's Reduced beta cell function in offspring of mothers with young-onset type 2 diabetes‏
670 ‎‡a  Author's Sequence data and association statistics from 12,940 type 2 diabetes cases and controls‏
670 ‎‡a  Author's Significant Linkage of BMI to Chromosome 10p in the U.K. Population and Evaluation of GAD2 as a Positional Candidate‏
670 ‎‡a  Author's Skin mini-erosion technique for monitoring metabolites in interstitial fluid: its feasibility demonstrated by OGTT results in diabetic and non-diabetic subjects‏
670 ‎‡a  Author's Synchronous Interactions Foster Empathy‏
670 ‎‡a  Author's Telemedicine Technologies for Diabetes in Pregnancy: A Systematic Review and Meta-Analysis‏
670 ‎‡a  Author's The genetic architecture of type 2 diabetes‏
670 ‎‡a  Author's The incretin pathway as a new therapeutic target for obesity‏
670 ‎‡a  Author's The relationship between the insulin resistance syndrome and insulin sensitivity in the first-degree relatives of subjects with non-insulin dependent diabetes mellitus.‏
670 ‎‡a  Author's The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus.‏
670 ‎‡a  Author's The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults‏
670 ‎‡a  Author's Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes.‏
670 ‎‡a  Author's Three-year efficacy of complex insulin regimens in type 2 diabetes‏
670 ‎‡a  Author's Use and abuse of HOMA modeling‏
670 ‎‡a  Author's Validity of simplified protocols to estimate glomerular filtration rate using iohexol clearance‏
909 ‎‡a  (orcid) 0000000294861885‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000310072393‏ ‎‡9  1‏
909 ‎‡a  (scopus) 7403982206‏ ‎‡9  1‏
912 ‎‡a  sequencedataandassociationstatisticsfrom12940type2diabetescasesandcontrols‏ ‎‡A  Sequence data and association statistics from 12,940 type 2 diabetes cases and controls‏ ‎‡9  1‏
912 ‎‡a  geneticarchitectureoftype2diabetes‏ ‎‡A  The genetic architecture of type 2 diabetes‏ ‎‡9  1‏
912 ‎‡a  lowfrequencyinactivatingakt2variantenrichedinthefinnishpopulationisassociatedwithfastinginsulinlevelsandtype2diabetesrisk‏ ‎‡A  A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk‏ ‎‡9  1‏
912 ‎‡a  erratumsequencedataandassociationstatisticsfrom12940type2diabetescasesandcontrols‏ ‎‡A  Erratum: Sequence data and association statistics from 12,940 type 2 diabetes cases and controls‏ ‎‡9  1‏
919 ‎‡a  significantlinkageofbmitochromosome10pintheukpopulationandevaluationofgad2asapositionalcandidate‏ ‎‡A  Significant Linkage of BMI to Chromosome 10p in the U.K. Population and Evaluation of GAD2 as a Positional Candidate‏ ‎‡9  1‏
919 ‎‡a  skinminierosiontechniqueformonitoringmetabolitesininterstitialfluiditsfeasibilitydemonstratedbyogttresultsindiabeticandnondiabeticsubjects‏ ‎‡A  Skin mini-erosion technique for monitoring metabolites in interstitial fluid: its feasibility demonstrated by OGTT results in diabetic and non-diabetic subjects‏ ‎‡9  1‏
919 ‎‡a  synchronousinteractionsfosterempathy‏ ‎‡A  Synchronous Interactions Foster Empathy‏ ‎‡9  1‏
919 ‎‡a  telemedicinetechnologiesfordiabetesinpregnancyasystematicreviewandmetaanalysis‏ ‎‡A  Telemedicine Technologies for Diabetes in Pregnancy: A Systematic Review and Meta-Analysis‏ ‎‡9  1‏
919 ‎‡a  incretinpathwayasanewtherapeutictargetforobesity‏ ‎‡A  The incretin pathway as a new therapeutic target for obesity‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweentheinsulinresistancesyndromeandinsulinsensitivityinthe1degreerelativesofsubjectswithnoninsulindependentdiabetesmellitus‏ ‎‡A  The relationship between the insulin resistance syndrome and insulin sensitivity in the first-degree relatives of subjects with non-insulin dependent diabetes mellitus.‏ ‎‡9  1‏
919 ‎‡a  relativerisksofhyperglycaemiaobesityanddyslipidaemiaintherelativesofpatientswithtype2diabetesmellitus‏ ‎‡A  The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus.‏ ‎‡9  1‏
919 ‎‡a  variablenumberoftandemrepeatsupstreamoftheinsulingeneisasusceptibilitylocusforlatentautoimmunediabetesinadults‏ ‎‡A  The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults‏ ‎‡9  1‏
919 ‎‡a  therapeuticinterventionintheglp1pathwayintype2diabetes‏ ‎‡A  Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes.‏ ‎‡9  1‏
919 ‎‡a  3yearefficacyofcomplexinsulinregimensintype2diabetes‏ ‎‡A  Three-year efficacy of complex insulin regimens in type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  useandabuseofhomamodeling‏ ‎‡A  Use and abuse of HOMA modeling‏ ‎‡9  1‏
919 ‎‡a  validityofsimplifiedprotocolstoestimateglomerularfiltrationrateusingiohexolclearance‏ ‎‡A  Validity of simplified protocols to estimate glomerular filtration rate using iohexol clearance‏ ‎‡9  1‏
919 ‎‡a  genomewidescanforlocipredisposingtotype2diabetesinaukpopulation‏ ‎‡A  A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population‏ ‎‡9  1‏
919 ‎‡a  genomewidescanforlocipredisposingtotype2diabetesinaukpopulationthediabetesukwarren2repositoryanalysisof573pedigreesprovidesindependentreplicationofasusceptibilitylocusonchromosome1q‏ ‎‡A  A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q‏ ‎‡9  1‏
919 ‎‡a  methodforassessingqualityofcontrolfromglucoseprofiles‏ ‎‡A  A method for assessing quality of control from glucose profiles.‏ ‎‡9  1‏
919 ‎‡a  additionofbiphasicprandialorbasalinsulintooraltherapyintype2diabetes‏ ‎‡A  Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  associationanalysisofthehlageneregioninlatentautoimmunediabetesinadults‏ ‎‡A  An association analysis of the HLA gene region in latent autoimmune diabetes in adults.‏ ‎‡9  1‏
919 ‎‡a  increaseininsulinsensitivityandbasalbetacellfunctionindiabeticsubjectstreatedwithpioglitazoneinaplacebocontrolledrandomizedstudy‏ ‎‡A  An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.‏ ‎‡9  1‏
919 ‎‡a  analysisofthecontributiontotype2diabetessusceptibilityofsequencevariationinthegeneencodingstearoylcoadesaturaseakeyregulatoroflipidandcarbohydratemetabolism‏ ‎‡A  Analysis of the contribution to type 2 diabetes susceptibility of sequence variation in the gene encoding stearoyl-CoA desaturase, a key regulator of lipid and carbohydrate metabolism‏ ‎‡9  1‏
919 ‎‡a  apolipoproteinegenotypeisletamyloiddepositionandseverityoftype2diabetes‏ ‎‡A  Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  arylhydrocarbonreceptornucleartranslocatorlikebmal1isassociatedwithsusceptibilitytohypertensionandtype2diabetes‏ ‎‡A  Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  associationandhaplotypeanalysisoftheinsulindegradingenzymeidegeneastrongpositionalandbiologicalcandidatefortype2diabetessusceptibility‏ ‎‡A  Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility‏ ‎‡9  1‏
919 ‎‡a  associationstudiesofinsulinreceptorsubstrate1gene‏ ‎‡A  Association Studies of Insulin Receptor Substrate 1 Gene‏ ‎‡9  1‏
919 ‎‡a  associationstudiesofinsulinreceptorsubstrate1geneirs1variantsintype2diabetessamplesenrichedforfamilyhistoryandearlyageofonset‏ ‎‡A  Association Studies of Insulin Receptor Substrate 1 Gene (IRS1) Variants in Type 2 Diabetes Samples Enriched for Family History and Early Age of Onset‏ ‎‡9  1‏
919 ‎‡a  butyrylcholinesterasekvariantonchromosome3qisassociatedwithtype2diabetesinwhitecaucasiansubjects‏ ‎‡A  Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.‏ ‎‡9  1‏
919 ‎‡a  clinicalusefulnessofcystatin100fortheestimationofglomerularfiltrationrateintype1diabetesreproducibilityandaccuracycomparedwithstandardmeasuresandiohexolclearance‏ ‎‡A  Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance.‏ ‎‡9  1‏
919 ‎‡a  comparingtheefficacyofamobilephonebasedbloodglucosemanagementsystemwithstandardcliniccareinwomenwithgestationaldiabetesrandomizedcontrolledtrial‏ ‎‡A  Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in Women With Gestational Diabetes: Randomized Controlled Trial.‏ ‎‡9  1‏
919 ‎‡a  determinantsofwithinsubjectvariationoffastingserumleptinconcentrationsinhealthysubjects‏ ‎‡A  Determinants of within-subject variation of fasting serum leptin concentrations in healthy subjects.‏ ‎‡9  1‏
919 ‎‡a  erectiledysfunctionamongmenwithdiabetesisstronglyassociatedwithprematureejaculationandreducedlibido‏ ‎‡A  Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido‏ ‎‡9  1‏
919 ‎‡a  erectiledysfunctionindiabetesmellitus‏ ‎‡A  Erectile dysfunction in diabetes mellitus.‏ ‎‡9  1‏
919 ‎‡a  ethnicdifferencesinsexualdysfunctionamongdiabeticandnondiabeticmalestheoxfordsexualdysfunctionstudy‏ ‎‡A  Ethnic differences in sexual dysfunction among diabetic and nondiabetic males: the Oxford Sexual Dysfunction Study‏ ‎‡9  1‏
919 ‎‡a  evidenceforlinkageofstaturetochromosome3p26inalargeukfamilydatasetascertainedfortype2diabetes‏ ‎‡A  Evidence for linkage of stature to chromosome 3p26 in a large U.K. Family data set ascertained for type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  evidencefromalargeukfamilycollectionthatgenesinfluencingageofonsetoftype2diabetesmaptochromosome12pandtothemody3niddm2locuson12q24‏ ‎‡A  Evidence From a Large U.K. Family Collection That Genes Influencing Age of Onset of Type 2 Diabetes Map to Chromosome 12p and to the MODY3/NIDDM2 Locus on 12q24‏ ‎‡9  1‏
919 ‎‡a  examiningtherelationshipsbetweenthepro12alavariantinppargandtype2diabetesrelatedtraitsinuksamples‏ ‎‡A  Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes-related traits in UK samples.‏ ‎‡9  1‏
919 ‎‡a  gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes‏ ‎‡A  GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  gadautoantibodiesandepitopereactivitiespersistafterdiagnosisinlatentautoimmunediabetesinadultsbutdonotpredictdiseaseprogressionukpds77‏ ‎‡A  GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77‏ ‎‡9  1‏
919 ‎‡a  glucokinasedeficiencyresultsinabetacelldisordercharacterisedbynormalfastingplasmaproinsulinconcentrations‏ ‎‡A  Glucokinase deficiency results in a beta-cell disorder characterised by normal fasting plasma proinsulin concentrations.‏ ‎‡9  1‏
919 ‎‡a  glucosetoleranceinruraldiabeticthais1degreerelativesandnondiabeticcontrols‏ ‎‡A  Glucose tolerance in rural diabetic Thais, first-degree relatives and non-diabetic controls.‏ ‎‡9  1‏
919 ‎‡a  guthormonesincretinmimeticsandgliptinsnewunderstandingandnoveltherapiesintype2diabetes‏ ‎‡A  Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  heritabilityestimatesforbetacellfunctionandfeaturesoftheinsulinresistancesyndromeinukfamilieswithanincreasedsusceptibilitytotype2diabetes‏ ‎‡A  Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.‏ ‎‡9  1‏
919 ‎‡a  humancalciumcalmodulindependentproteinkinase2gammagenecamk2gcloninggenomicstructureanddetectionofvariantsinsubjectswithtype2diabetes‏ ‎‡A  Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.‏ ‎‡9  1‏
919 ‎‡a  hyperglycaemicsiblingsoftype2noninsulindependentdiabeticpatientshaveincreasedpai1centralobesityandinsulinresistancecomparedwiththeirpairednormoglycaemicsibling‏ ‎‡A  Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.‏ ‎‡9  1‏
919 ‎‡a  impendingtype2diabetes‏ ‎‡A  Impending type 2 diabetes.‏ ‎‡9  1‏
919 ‎‡a  insulinsensitivityatdiagnosisoftype2diabetesisnotassociatedwithsubsequentcardiovasculardisease‏ ‎‡A  Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease‏ ‎‡9  1‏
919 ‎‡a  insulinsensitivityatdiagnosisoftype2diabetesisnotassociatedwithsubsequentcardiovasculardiseaseukpds67‏ ‎‡A  Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).‏ ‎‡9  1‏
919 ‎‡a  interactionbetweenspecificfattyacidsglp1andinsulinsecretioninhumans‏ ‎‡A  Interaction between specific fatty acids, GLP-1 and insulin secretion in humans‏ ‎‡9  1‏
919 ‎‡a  isletamyloidpolypeptidegenepromoterpolymorphismsarenotassociatedwithtype2diabetesorwiththeseverityofisletamyloidosis‏ ‎‡A  Islet amyloid polypeptide gene promoter polymorphisms are not associated with Type 2 diabetes or with the severity of islet amyloidosis‏ ‎‡9  1‏
919 ‎‡a  largescaleassociationstudiesofvariantsingenesencodingthepancreaticbetacellkatpchannelsubunitskir62‏ ‎‡A  Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2‏ ‎‡9  1‏
919 ‎‡a  largescaleassociationstudiesofvariantsingenesencodingthepancreaticbetacellkatpchannelsubunitskir62kcnj11andsur1abcc8confirmthatthekcnj11e23kvariantisassociatedwithtype2diabetes‏ ‎‡A  Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes‏ ‎‡9  1‏
919 ‎‡a  largescalestudiesoftheassociationbetweenvariationatthetnfltalocusandsusceptibilitytotype2diabetes‏ ‎‡A  Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes.‏ ‎‡9  1‏
919 ‎‡a  metaanalysisandalargeassociationstudyconfirmaroleforcalpain10variationintype2diabetessusceptibility‏ ‎‡A  Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility‏ ‎‡9  1‏
919 ‎‡a  nearnormalisationofdiurnalglucoseconcentrationsbycontinuousadministrationofglucagonlikepeptide1‏ ‎‡A  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1‏ ‎‡9  1‏
919 ‎‡a  nearnormalisationofdiurnalglucoseconcentrationsbycontinuousadministrationofglucagonlikepeptide1glp1insubjectswithniddm‏ ‎‡A  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.‏ ‎‡9  1‏
919 ‎‡a  noevidenceforlinkageatcandidatetype2diabetessusceptibilitylocionchromosomes12and20inunitedkingdomcaucasians‏ ‎‡A  No Evidence for Linkage at Candidate Type 2 Diabetes Susceptibility Loci on Chromosomes 12 and 20 in United Kingdom Caucasians‏ ‎‡9  1‏
919 ‎‡a  normalreferencerangeformeantissueglucoseandglycemicvariabilityderivedfromcontinuousglucosemonitoringforsubjectswithoutdiabetesindifferentethnicgroups‏ ‎‡A  Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups‏ ‎‡9  1‏
919 ‎‡a  polymorphismsintype2sh2domaincontaininginositol5phosphataseinppl1ship2areassociatedwithphysiologicalabnormalitiesofthemetabolicsyndrome‏ ‎‡A  Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome‏ ‎‡9  1‏
919 ‎‡a  prevalenceandpathophysiologyofimpairedglucosetolerancein3differenthighriskwhitegroups‏ ‎‡A  Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.‏ ‎‡9  1‏
919 ‎‡a  ptenmutationsasacauseofconstitutiveinsulinsensitivityandobesity‏ ‎‡A  PTEN mutations as a cause of constitutive insulin sensitivity and obesity.‏ ‎‡9  1‏
919 ‎‡a  reducedbetacellfunctioninoffspringofmotherswithyoungonsettype2diabetes‏ ‎‡A  Reduced beta cell function in offspring of mothers with young-onset type 2 diabetes‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  SUDOC|188362916‏
996 ‎‡2  ISNI|0000000453189222‏
996 ‎‡2  NTA|067855873‏
996 ‎‡2  BLBNB|000524412‏
996 ‎‡2  BIBSYS|1460961538050‏
996 ‎‡2  LC|nb2007014425‏
996 ‎‡2  LC|no2013101498‏
996 ‎‡2  SUDOC|169125556‏
996 ‎‡2  LC|n 2014065555‏
996 ‎‡2  J9U|987007447249805171‏
996 ‎‡2  CAOONL|ncf11632843‏
996 ‎‡2  SUDOC|165647477‏
996 ‎‡2  KRNLK|KAC200504340‏
996 ‎‡2  LC|no 95008230‏
996 ‎‡2  NTA|408640820‏
996 ‎‡2  LC|n 82026936‏
996 ‎‡2  ISNI|0000000036520447‏
996 ‎‡2  SUDOC|176785671‏
996 ‎‡2  ISNI|0000000446467490‏
996 ‎‡2  ISNI|0000000385622337‏
996 ‎‡2  BNE|XX1060641‏
996 ‎‡2  LC|no2008114220‏
996 ‎‡2  LC|n 95075833‏
996 ‎‡2  LC|n 2006093382‏
996 ‎‡2  NII|DA10228592‏
996 ‎‡2  DNB|1028583753‏
996 ‎‡2  SUDOC|177678526‏
996 ‎‡2  NTA|11019859X‏
996 ‎‡2  NII|DA13720567‏
996 ‎‡2  N6I|vtls000036898‏
996 ‎‡2  ISNI|0000000059234259‏
996 ‎‡2  ISNI|0000000046768737‏
996 ‎‡2  SUDOC|260818453‏
996 ‎‡2  LC|n 85027479‏
996 ‎‡2  DNB|1128344114‏
996 ‎‡2  RERO|A027576961‏
996 ‎‡2  LC|n 90641632‏
996 ‎‡2  LC|n 86108647‏
996 ‎‡2  J9U|987007433691205171‏
996 ‎‡2  NTA|326154833‏
996 ‎‡2  BNF|17168175‏
996 ‎‡2  LC|n 92035891‏
996 ‎‡2  LC|no2015132783‏
996 ‎‡2  PLWABN|9810638917905606‏
996 ‎‡2  SUDOC|138036551‏
996 ‎‡2  LC|nb2018012553‏
996 ‎‡2  CAOONL|ncf10884953‏
996 ‎‡2  ISNI|0000000434242905‏
996 ‎‡2  NII|DA07974593‏
996 ‎‡2  ISNI|000000039856392X‏
996 ‎‡2  ISNI|0000000052897439‏
996 ‎‡2  NTA|395541549‏
996 ‎‡2  NTA|166508993‏
996 ‎‡2  ISNI|0000000067072181‏
996 ‎‡2  SUDOC|158820029‏
996 ‎‡2  J9U|987007264537005171‏
996 ‎‡2  ISNI|0000000440107865‏
996 ‎‡2  BNF|13802279‏
996 ‎‡2  NTA|321346262‏
996 ‎‡2  NKC|mzk20221153302‏
996 ‎‡2  RERO|A017017923‏
996 ‎‡2  SUDOC|259993913‏
996 ‎‡2  NUKAT|n 2003045533‏
996 ‎‡2  RERO|A019207826‏
996 ‎‡2  PLWABN|9810649420305606‏
996 ‎‡2  PTBNP|1196361‏
996 ‎‡2  CAOONL|ncf10204208‏
996 ‎‡2  DNB|170929094‏
996 ‎‡2  SUDOC|257363815‏
996 ‎‡2  LC|n 81112433‏
996 ‎‡2  LC|n 2015060634‏
996 ‎‡2  LC|nr 92037453‏
996 ‎‡2  SUDOC|184031389‏
996 ‎‡2  ISNI|0000000072833715‏
996 ‎‡2  LC|no2017069115‏
996 ‎‡2  J9U|987007310176405171‏
996 ‎‡2  DBC|87097991365545‏
996 ‎‡2  LC|no2015160500‏
996 ‎‡2  LC|nr 93012899‏
996 ‎‡2  NTA|17197736X‏
996 ‎‡2  BNF|16231617‏
996 ‎‡2  DNB|1224894863‏
996 ‎‡2  NII|DA02954533‏
996 ‎‡2  SUDOC|076391655‏
996 ‎‡2  ISNI|0000000032247930‏
996 ‎‡2  SUDOC|260835617‏
996 ‎‡2  NTA|131498703‏
996 ‎‡2  BNF|16683514‏
996 ‎‡2  ISNI|0000000457538063‏
996 ‎‡2  UIY|000063508‏
996 ‎‡2  NTA|195543130‏
996 ‎‡2  NTA|133984036‏
996 ‎‡2  KRNLK|KAC200902306‏
996 ‎‡2  SUDOC|263722724‏
996 ‎‡2  NUKAT|n 2021005926‏
996 ‎‡2  DNB|1159153582‏
996 ‎‡2  BIBSYS|90919270‏
996 ‎‡2  RERO|A016685277‏
996 ‎‡2  J9U|987007308840505171‏
996 ‎‡2  SUDOC|278448909‏
996 ‎‡2  LC|n 2012187581‏
996 ‎‡2  RERO|A003517494‏
996 ‎‡2  LC|n 2004055798‏
996 ‎‡2  ISNI|0000000081640077‏
996 ‎‡2  SUDOC|084027827‏
996 ‎‡2  ISNI|0000000043373860‏
996 ‎‡2  ISNI|0000000108036030‏
996 ‎‡2  LC|n 94011736‏
996 ‎‡2  LC|n 83071492‏
996 ‎‡2  DNB|1031652809‏
996 ‎‡2  RERO|A025031048‏
996 ‎‡2  JPG|500003229‏
996 ‎‡2  SUDOC|263627403‏
996 ‎‡2  CAOONL|ncf10702114‏
996 ‎‡2  DNB|134760239‏
996 ‎‡2  LC|nr 94033264‏
996 ‎‡2  ISNI|0000000369935640‏
996 ‎‡2  BNCHL|10000000000000000224829‏
996 ‎‡2  SUDOC|258215445‏
996 ‎‡2  LC|no2006098345‏
996 ‎‡2  SUDOC|147029651‏
996 ‎‡2  NTA|074877836‏
996 ‎‡2  SUDOC|177444991‏
996 ‎‡2  SUDOC|146469011‏
996 ‎‡2  LC|n 84110782‏
996 ‎‡2  LC|n 81067490‏
996 ‎‡2  LC|n 79026657‏
996 ‎‡2  SUDOC|261567934‏
996 ‎‡2  LC|nb2015011568‏
996 ‎‡2  J9U|987007604311805171‏
996 ‎‡2  SUDOC|168241994‏
996 ‎‡2  SUDOC|185981712‏
996 ‎‡2  ISNI|0000000457494996‏
996 ‎‡2  DNB|1271818973‏
996 ‎‡2  LC|no 00007691‏
996 ‎‡2  ISNI|0000000074021585‏
996 ‎‡2  RERO|A027405114‏
996 ‎‡2  BNF|17786590‏
996 ‎‡2  BNF|13929045‏
996 ‎‡2  SUDOC|276805089‏
996 ‎‡2  SUDOC|256026793‏
996 ‎‡2  NDL|00470433‏
996 ‎‡2  DNB|1216072477‏
996 ‎‡2  J9U|987007298514005171‏
996 ‎‡2  J9U|987007369261105171‏
996 ‎‡2  LC|n 2005024837‏
996 ‎‡2  RERO|A018762215‏
996 ‎‡2  SUDOC|177594357‏
996 ‎‡2  CAOONL|ncf11035907‏
996 ‎‡2  LC|no2014111520‏
996 ‎‡2  PTBNP|1203765‏
996 ‎‡2  J9U|987007524445305171‏
996 ‎‡2  ISNI|000000038786484X‏
996 ‎‡2  LC|no 95042794‏
996 ‎‡2  NII|DA11129778‏
996 ‎‡2  ISNI|000000036724802X‏
996 ‎‡2  LC|n 84108475‏
996 ‎‡2  DNB|1220993824‏
996 ‎‡2  J9U|987007583986405171‏
996 ‎‡2  RERO|A019154302‏
996 ‎‡2  BNF|13973346‏
996 ‎‡2  LC|no2016155291‏
996 ‎‡2  ERRR|a12025604‏
996 ‎‡2  BIBSYS|1560455410142‏
996 ‎‡2  JPG|500246487‏
996 ‎‡2  N6I|vtls000047520‏
996 ‎‡2  NTA|363419829‏
996 ‎‡2  BNE|XX4876364‏
996 ‎‡2  ISNI|0000000118449066‏
996 ‎‡2  SUDOC|148951651‏
996 ‎‡2  DNB|125532245‏
996 ‎‡2  SUDOC|07102929X‏
996 ‎‡2  ISNI|0000000118449218‏
996 ‎‡2  J9U|987007374769505171‏
996 ‎‡2  SUDOC|184124964‏
996 ‎‡2  NDL|033403966‏
996 ‎‡2  SUDOC|175734143‏
996 ‎‡2  NLA|000035071720‏
996 ‎‡2  LC|n 78041285‏
996 ‎‡2  RERO|A027312807‏
996 ‎‡2  BIBSYS|90706874‏
996 ‎‡2  BNF|12197834‏
996 ‎‡2  LC|n 2012024736‏
996 ‎‡2  ISNI|0000000049287517‏
996 ‎‡2  NUKAT|n 2009102370‏
996 ‎‡2  NKC|vse20231192288‏
996 ‎‡2  DE633|pe179655‏
996 ‎‡2  NUKAT|n 2003082915‏
996 ‎‡2  B2Q|0000321667‏
996 ‎‡2  SUDOC|030594731‏
996 ‎‡2  BNF|16952727‏
996 ‎‡2  BNC|981058517536206706‏
996 ‎‡2  ISNI|0000000084772876‏
996 ‎‡2  BIBSYS|8056881‏
996 ‎‡2  DNB|1045177059‏
996 ‎‡2  PLWABN|9813167312705606‏
996 ‎‡2  NTA|074061127‏
996 ‎‡2  DNB|1227248202‏
996 ‎‡2  ISNI|0000000116037148‏
996 ‎‡2  ISNI|0000000109747299‏
996 ‎‡2  J9U|987007289306605171‏
996 ‎‡2  DNB|124579440X‏
996 ‎‡2  BIBSYS|90069645‏
996 ‎‡2  CAOONL|ncf11370550‏
996 ‎‡2  BNF|16769463‏
996 ‎‡2  DNB|143336347‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏